These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10974616)

  • 21. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
    Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabotropic glutamate2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans.
    Agorastos A; Demiralay C; Stiedl O; Muhtz C; Wiedemann K; Kellner M
    Int Clin Psychopharmacol; 2016 May; 31(3):176-8. PubMed ID: 26752621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
    Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
    Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects.
    Jerabek I; Boulenger JP; Bradwejn J; Lavallée YJ; Jolicoeur FB
    Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):149-55. PubMed ID: 10082241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
    Maron E; Tõru I; Vasar V; Shlik J
    J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
    Plag J; Gaudlitz K; Zschucke E; Yassouridis A; Pyrkosch L; Wittmann A; Holsboer F; Ströhle A
    Curr Pharm Des; 2012; 18(35):5619-26. PubMed ID: 22632477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men.
    Agorastos A; Kellner M; Stiedl O; Muhtz C; Wiedemann K; Demiralay C
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers.
    Koszycki D; Zacharko RM; Le Melledo JM; Young SN; Bradwejn J
    Biol Psychiatry; 1996 Oct; 40(7):648-55. PubMed ID: 8886299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety.
    Schunck T; Erb G; Mathis A; Gilles C; Namer IJ; Hode Y; Demaziere A; Luthringer R; Macher JP
    Neuroimage; 2006 Jul; 31(3):1197-208. PubMed ID: 16600640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers.
    Koszycki D; Bradwejn J; Bourin M
    Eur Neuropsychopharmacol; 1991 May; 1(2):137-41. PubMed ID: 1821703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males.
    Goettel M; Fuertig R; Mack SR; Just S; Sharma V; Wunder A; den Boer J
    CNS Drugs; 2023 Dec; 37(12):1099-1109. PubMed ID: 38019356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A; Holsboer F; Rupprecht R
    Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity to cholecystokinin-tetrapeptide in major depression.
    Koszycki D; Copen J; Bradwejn J
    J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 10 microg CCK-4 premedication and 35% CO2 challenge in healthy volunteers.
    Schruers K; Pols H; Overbeek T; Griez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 Apr; 24(3):409-18. PubMed ID: 10836489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.
    van Megen HJ; Westenberg HG; Den Boer JA; Kahn RS
    Eur Neuropsychopharmacol; 1996 Aug; 6(3):187-94. PubMed ID: 8880078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects.
    Maron E; Tõru I; Mäemets K; Sepp S; Vasar V; Shlik J; Zharkovsky A
    J Psychopharmacol; 2009 Jun; 23(4):460-4. PubMed ID: 18562429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
    Bradwejn J; Koszycki D; Meterissian G
    Can J Psychiatry; 1990 Feb; 35(1):83-5. PubMed ID: 2180549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers.
    Shlik J; Zhou Y; Koszycki D; Vaccarino FJ; Bradwejn J
    J Psychopharmacol; 1999 Dec; 13(4):385-90. PubMed ID: 10667615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 5-HTTLPR genotype modulates heart rate variability and its adjustment by pharmacological panic challenge in healthy men.
    Agorastos A; Kellner M; Stiedl O; Muhtz C; Becktepe JS; Wiedemann K; Demiralay C
    J Psychiatr Res; 2014 Mar; 50():51-8. PubMed ID: 24342768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
    Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.